The Effect of Beetroot Juice Supplementation Dose on Neuromuscular Performance During Resistance Exercise

July 16, 2023 updated by: Rachel Tan, Pepperdine University
Dietary nitrate supplementation, administered in the form of nitrate-rich beetroot juice, has been shown to improve exercise performance and may have more pronounced effects on exercise that requires high-power and high-velocity muscle contraction such as weightlifting and body-mass resisted exercise (i.e, resistance exercise). However, limited data are available that have examined the potential performance enhancing effect of beetroot juice in resistance exercise. Moreover, there is no information on the dose of nitrate required for performance enhancing effects during resistance exercise which limits its widespread use to enhance performance. Therefore, the investigators will assess if supplementing the diet with nitrate-rich beetroot juice impacts resistance exercise performance (e.g., power, velocity), when compared to supplementing the diet with nitrate-depleted beetroot juice (i.e. placebo). The investigators will also investigate the dose-response effect of beetroot juice on resistance exercise performance by providing a low, moderate, and high nitrate dose of concentrated beetroot juice. The results of this study will improve understanding of whether beetroot juice influences resistance exercise performance and will provide insight on whether different doses of beetroot juice influence the efficacy of nitrate supplementation on resistance exercise performance. Together, these data will guide supplementation strategies for enhancing resistance exercise performance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Supplementation with inorganic nitrate, which is most commonly administered in the form of concentrated nitrate-rich beetroot juice shots, has emerged as an ergogenic nutritional strategy. Beetroot juice ingestion has been reported to enhance endurance and high-intensity intermittent exercise performance in running and cycling. These improvements are attributed to augmented muscle contractility, force production and blood flow distribution, specifically in muscle groups comprised predominantly of type II muscle fibers. Together, such changes provide a strong physiological rationale supporting the potential for dietary nitrate to enhance high-power and high-velocity muscle contractions since type II muscle fibers are heavily activated during these tasks. However, the influence of dietary nitrate on resistance exercise performance is substantially underdeveloped with most previous studies having assessed the effect of nitrate supplementation on running and cycling endurance and high-intensity intermittent exercise. Moreover, there is no information on the dose of nitrate required to evoke ergogenic effects during resistance exercise, which greatly hinders the potential implementation of beetroot juice as a research-informed performance enhancing supplement for resistance exercise. Thus, the proposed project will investigate if acute dietary nitrate ingestion, provided as nitrate-rich beetroot juice, elicits improvements in various neuromuscular performance parameters (e.g., power, velocity) during resistance exercise performance when compared to supplementing the diet with a nitrate-depleted beetroot juice placebo. The investigators will also investigate the dose-response effect of beetroot juice on resistance exercise performance by providing low (70 ml i.e., ~6.5 mmol or ~400 mg of nitrate), moderate (140 ml i.e., ~13 mmol or ~800 mg of nitrate) and a high nitrate dose (280 ml i.e., ~26 mmol or ~1600 mg of nitrate) of concentrated beetroot juice. This project will provide insight to practitioners (coaches/athletes) aiming to enhance performance in settings where muscular power and speed are key determinants for success, as well as to scientists exploring the efficacy of beetroot juice as a form of dietary nitrate supplementation to improve muscle contractile function.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
18

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Recreationally active males who performed resistance exercise at least twice weekly for the last two years

Exclusion Criteria:

  • individuals with contraindications to exercise, cardiometabolic disease, currently consuming dietary supplements containing caffeine, sodium bicarbonate, creatine, beta-alanine, and/or NO precursor supplements (i.e., NO3-, arginine, citrulline, antioxidants), females, and smokers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: BR-HIGH
Participants will ingest an elevated dose of nitrate 2.5 hours prior to exercise.
Dietary supplement: BR-HIGH
4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
Experimental: BR-MOD
Participants will ingest a moderate dose of nitrate 2.5 hours prior to exercise.
Dietary supplement: BR-MOD
2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
Experimental: BR-LOW
Participants will ingest a low dose of nitrate 2.5 hours prior to exercise.
Dietary supplement: BR-LOW
1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
Placebo Comparator: PL
Participants will ingest a negligible amount of nitrate 2.5 hours prior to exercise.
Dietary supplement: PL
4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Plasma nitrate
Time Frame: Through study completion, at least 1 year
Plasma nitrate concentrations in each condition from blood samples draw at rest prior to exercise, and analyzed using gas phase chemiluminescence
Through study completion, at least 1 year
Plasma nitrite
Time Frame: Through study completion, at least 1 year
Plasma nitrite concentrations in each condition from blood samples draw at rest prior to exercise, and analyzed using gas phase chemiluminescence
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
Peak force will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
average propulsion force will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
rate of power development will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
peak positive power will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
concentric mean power will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
jump height will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
takeoff velocity will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
flight time will be measured using a force place.
Through study completion, at least 1 year
Neuromuscular performance during countermovement jumps
Time Frame: Through study completion, at least 1 year
Peak force, average propulsion force, rate of power development, peak positive power, concentric mean power, jump height, takeoff velocity, flight time will be measured using a force place.
Through study completion, at least 1 year
Peak power
Time Frame: Through study completion, at least 1 year
Power will be measured using a linear transducer with the highest value will be recorded for peak power
Through study completion, at least 1 year
Mean power
Time Frame: Through study completion, at least 1 year
Power will be measured using a linear transducer and will be averaged across sets for the determination of mean power
Through study completion, at least 1 year
Mean velocity
Time Frame: Through study completion, at least 1 year
Velocity will be measured using a linear transducer and will be averaged across sets for the determination of mean velocity
Through study completion, at least 1 year
Peak velocity
Time Frame: Through study completion, at least 1 year
Velocity will be measured using a linear transducer the highest value will be retained for peak velocity
Through study completion, at least 1 year

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Mood
Time Frame: Through study completion, at least 1 year
24 items representing six subscales (i.e., anger, confusion, depression, fatigue, tension, vigour; four-items per subscale) will be captured using a five-point Likert scale (i.e., 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely)
Through study completion, at least 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Pepperdine University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Rachel Tan, PhD, Pepperdine University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 23, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 28, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 28, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 16, 2023

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 24, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 24, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 16, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RT12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings